Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease
Utilizing structure-based drug design, a 4-aminoimidazole heterocyclic core was synthesized as a replacement for a 2-aminothiazole due to potential metabolically mediated toxicity. The synthetic route utilized allowed for ready synthesis of 1-substituted-4-aminoimidazoles. SAR exploration resulted in the identification of a novel cis-substituted cyclobutyl group that gave improved enzyme and cellular potency against cdk5/p25 with up to 30-fold selectivity over cdk2/cyclin E.
Helal, Christopher J.,Kang, Zhijun,Lucas, John C.,Gant, Thomas,Ahlijanian, Michael K.,Schachter, Joel B.,Richter, Karl E.G.,Cook, James M.,Menniti, Frank S.,Kelly, Kristin,Mente, Scot,Pandit, Jay,Hosea, Natalie
supporting information; experimental part
p. 5703 - 5707
(2010/04/30)
More Articles about upstream products of 4640-44-2